Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEquity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Pharming (PHAR) EBITDA (2020 - 2025)

Historic EBITDA for Pharming (PHAR) over the last 6 years, with Q3 2025 value amounting to $22.9 million.

  • Pharming's EBITDA rose 45664.56% to $22.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.0 million, marking a year-over-year increase of 12972.94%. This contributed to the annual value of -$8.6 million for FY2024, which is 6003.34% down from last year.
  • Pharming's EBITDA amounted to $22.9 million in Q3 2025, which was up 45664.56% from $3.8 million recorded in Q2 2025.
  • Pharming's 5-year EBITDA high stood at $6.3 billion for Q1 2021, and its period low was -$6.2 billion during Q2 2021.
  • For the 5-year period, Pharming's EBITDA averaged around -$100433.5, with its median value being -$3.5 million (2021).
  • As far as peak fluctuations go, Pharming's EBITDA soared by 56480.42% in 2022, and later crashed by 14698.88% in 2023.
  • Over the past 5 years, Pharming's EBITDA (Quarter) stood at -$14.6 million in 2021, then skyrocketed by 30.27% to -$10.2 million in 2022, then skyrocketed by 47.19% to -$5.4 million in 2023, then crashed by 60.03% to -$8.6 million in 2024, then soared by 365.25% to $22.9 million in 2025.
  • Its EBITDA stands at $22.9 million for Q3 2025, versus $3.8 million for Q2 2025 and -$7.0 million for Q1 2025.